There can be a particular kind of dismissal that follows diseases that come and go. A patient looks fine today; photos are dramatic, but the exam is unremarkable. The story sounds urgent, yet their skin has already changed by the time they reach the office.  

Chronic spontaneous urticaria (CSU) exists in the between. CSU is a disease of lesions, yes, but also of anticipation. Hives are only a visible part of a larger disordering of daily life, and that’s where broader clinical conversation is beginning to change.

The Exam Can Miss the Story

For years, urticaria has been handled as something to suppress. An antihistamine here, higher dose there, a steroid burst when the patient is miserable enough, or a long search for a trigger that may never declare itself. The approach is understandable. CSU can look episodic, even when it’s chronic. It can feel allergic, even when no reliable exposure is identified. It can appear straightforward until the history makes clear that the disease has been shaping a person’s sleep, travel, work, enjoyment, and sense of control for months or years.

In a recent Derms and Conditions discussion, Jason Hawkes, MD, frames CSU by returning to the biology. “Something’s activating these mast cells,” he says. Dr Hawkes traces the familiar pieces clinicians see again and again: IgE, IgG, eosinophils, basophils, itch, angioedema, autoantibodies, and immune activation that does not politely stay within the boundaries of one textbook category.

This is part of what makes CSU such an important disease to reconsider in the era of targeted therapy. It doesn’t look like atopic dermatitis, nor prurigo nodularis, or bullous pemphigoid. But visible phenotype is not the same as immunologic distance; Dr Hawkes describes IL-4 as a signal involved in type 2 differentiation, with downstream relevance across tissues and diseases.  

In CSU, he connects IL-4 and IL-13 to isotype class switching and autoantibody formation, and notes that activated mast cells themselves can produce type 2 cytokines, including IL-4, IL-13, and IL-31. The point is not to memorize a pathway diagram but recognize that CSU may deserve a longer clinical horizon than we have historically given it.

Patients are already exhausted when they reach the office. Many have cycled through antihistamines in a casual, inconsistent, or desperate way. Others have been through more extensive treatment attempts, including higher-dose antihistamines or prior biologic therapy. “The very first thing when I see these patients is I want to know what they’ve done,” says Dr Hawkes.

The Pattern Is No Pattern

That sounds simple, but it can really change the approach. Has the patient used a second-generation H1 antihistamine consistently? Have they titrated appropriately, up to a 4-fold dosing if tolerated? Are they mixing multiple agents in a way that feels aggressive but adds little? Are they describing CSU, or is the pattern more consistent with acute urticaria or chronic inducible urticaria?

“I can’t find a pattern, doesn’t matter if I stop milk or drink milk, eat gluten or gluten-free, happens in the night, happens the day, happens when I’m stressed, happens when I’m not stressed,” Dr Hawkes says, echoing the refrain he often hears from patients. That history, in all its frustration, is diagnostic in its own way. The absence of a clear trigger is part of the disease.

The same is true of the “looks fine today” patient. CSU asks clinicians to take the history seriously even when the exam underwhelms. It asks us to let photographs, sleep loss, treatment fatigue, angioedema anxiety, and the patient’s own account carry real clinical weight. After all, quality of life is usually what brings a patient to the office.  

Download our free Biologic Medications Quick Reference Chart

Building Toward Durable Control

Dupilumab, now indicated for patients with CSU who remain symptomatic despite H1 antihistamine treatment, enters a disease space that has lived primarily with allergy and immunology, shaped in part by the safety considerations around existing advanced therapy. For dermatology clinicians already familiar with dupilumab across inflammatory diseases, it’s a significant shift. CSU begins to look less like a condition to temporize and refer, and more like a chronic inflammatory disorder to recognize, counsel on, and manage with intention.

Still, long-term control requires patience. “I would encourage providers not to give up prior to six months unless there’s a true primary failure,” he says. That is a different conversation than the one clinicians may have in atopic dermatitis, where a poor response at three months can be more telling. CSU may take longer.

That timeline has real implications because patients want relief now. Corticosteroids can provide it, but there are tradeoffs. “It works. It’ll get people under control. But when they come off, we’ve had some very severe flares from that taper,” says Dr Hawkes. He uses steroids as a last resort, especially for patients who have already been exposed repeatedly over time. The clinical task is to bridge the patient safely while building toward durable control.

Perhaps that is the larger movement in CSU: away from episodic rescue as the default and toward intentional chronic disease management. Not every patient needs a biologic. Some will respond well once antihistamine therapy is optimized. Some will need escalation. Some won’t respond as hoped. But the decision should come from a clear-eyed understanding of the disease, not from the misleading comfort of an uneventful exam.

History highlights chronicity before it becomes obvious in the room. CSU becomes serious in the missed sleep, repeated steroid bursts, and the anxiety of not knowing when the skin will erupt again. And as targeted therapies expand the possibilities for long-term control, clinicians have an opportunity to listen more intently and meet the disease where patients have been living with it all along. 

Listen to the full episode, Chronic Hives Are Back! New Perspectives on Evaluation and Management, here.